Adma Biologics Inc Buchwert je Aktie
Was ist das Buchwert je Aktie von Adma Biologics Inc?
Buchwert je Aktie von Adma Biologics Inc ist 3.28
Was ist die Definition von Buchwert je Aktie?
Der Buchwert pro Aktie ist das Vermögen eines Unternehmens abzüglich der Verbindlichkeiten geteilt durch die Anzahl der ausstehenden Aktien.
The book value of a company is the value of its assets according to its balance sheet account balance. For assets, the value is based on the original cost of the asset less any depreciation, amortization or impairment costs made against the asset. Traditionally, a company's book value is its total assets minus intangible assets and liabilities. However, in practice, depending on the source of the calculation, book value may variably include goodwill, intangible assets, or both. The value inherent in its workforce, part of the intellectual capital of a company, is always ignored. The book value of a company may be also referred as with the term net asset value.
The book value per share is the the balance sheet equity value divided by the number of shares outstanding at the date of the balance sheet. Book value per share can be used to generate a measure of comprehensive earnings, when the opening and closing values are reconciled. The sale of shares/units by a business increases the total book value. Book value per share will increase if the additional shares are issued at a price higher than the pre-existing book value per share. The purchase of its own shares by a business will decrease total book value. Book value per share will decrease if more is paid for them than was received when originally issued. Dividends paid out will decrease book value per share value.
Buchwert je Aktie von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Adma Biologics Inc
Was macht Adma Biologics Inc?
adma is a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of primary immune deficiency disease (pidd) and certain infectious diseases. adma's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases. the target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease, or who may be immune-compromised for medical reasons. adma’s lead product candidate, ri-002, has completed a phase iii clinical trial in patients with pidd and has met the primary endpoint. a bla for ri-002 was accepted by the fda on september 18, 2015. the company has received u.s. patent 9,107,906. for more information, please visit the company's website at www.admabiologics.com.
Unternehmen mit buchwert je aktie ähnlich Adma Biologics Inc
- ValiRx plc hat Buchwert je Aktie von 3.27
- Caspian Sunrise plc hat Buchwert je Aktie von 3.27
- ADTRAN Inc hat Buchwert je Aktie von 3.27
- Innergex Renewable hat Buchwert je Aktie von 3.27
- Express hat Buchwert je Aktie von 3.27
- Uni-President China Ltd hat Buchwert je Aktie von 3.28
- Adma Biologics Inc hat Buchwert je Aktie von 3.28
- AerSale hat Buchwert je Aktie von 3.28
- Collins Foods hat Buchwert je Aktie von 3.28
- Teranga Gold hat Buchwert je Aktie von 3.28
- Smartgroup Ltd hat Buchwert je Aktie von 3.28
- Eagle Nice (International) hat Buchwert je Aktie von 3.28
- Adtran hat Buchwert je Aktie von 3.29